BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 10728597)

  • 1. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
    Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
    Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
    J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
    Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138.
    Dardari R; Hinderer W; Lang D; Benider A; El Gueddari B; Joab I; Benslimane A; Khyatti M
    J Clin Microbiol; 2001 Sep; 39(9):3164-70. PubMed ID: 11526145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
    Xia C; Zhu K; Zheng G
    Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgA directed against early antigen of Epstein-Barr virus is no specific marker for the diagnosis of nasopharyngeal carcinoma.
    Sigel G; Schillinger M; Henninger K; Bauer G
    J Med Virol; 1994 Jul; 43(3):222-7. PubMed ID: 7931181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J; Cui Z; Zheng Y; Li X; Chen Y
    Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
    Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma.
    Mathew A; Cheng HM; Sam CK; Joab I; Prasad U; Cochet C
    Cancer Immunol Immunother; 1994 Jan; 38(1):68-70. PubMed ID: 8299121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
    Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
    Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
    Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
    Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
    Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
    Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
    Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
    Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma.
    Wong MM; Lye MS; Cheng HM; Sam CK
    Asian Pac J Allergy Immunol; 2005 Mar; 23(1):65-7. PubMed ID: 15997877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.